• news.cision.com/
  • AstraZeneca/
  • ASTRAZENECA PLC ANNOUNCES ZURAMPIC (LESINURAD) APPROVED IN THE EUROPEAN UNION FOR PATIENTS WITH GOUT
English

ASTRAZENECA PLC ANNOUNCES ZURAMPIC (LESINURAD) APPROVED IN THE EUROPEAN UNION FOR PATIENTS WITH GOUT

Report this content

AstraZeneca today announced that the European Commission (EC) has granted marketing authorisation for ZurampicTM(lesinurad) 200mg in combination with a xanthine oxidase inhibitor (XOI) for the adjunctive treatment of hyperuricemia in adult gout patients (with or without tophi) who have not achieved target serum uric acid (sUA) levels with an adequate dose of an XOI alone.

Click on, or paste the following link into your web browser, to view the associated PDF document.

http://www.rns-pdf.londonstockexchange.com/rns/5248P_1-2016-2-18.pdf

Subscribe

Documents & Links